Vital Signs Podcast: EBR's major milestones in WiSE CRT commercialisation
Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.
In this episode Nadine chats to John McCutcheon, the President and CEO of EBR Systems (ASX:EBR).
EBR is focused on its lead technology, the WiSE CRT System, an innovative device designed to overcome the limitations of conventional Cardiac Resynchronisation Therapy (CRT) and is the only leadless left ventricular endocardial pacing (LVEP) device on the market.
The company recently received FDA approval for the device in the US, opening the door to a mega market opportunity in one of the worlds largest healthcare markets.
Earlier this month, the first two US commercial patients were treated with WiSE ahead of the company's reimbursement milestones, further demonstrating the clinical importance of the device.
In this episode McCutcheon explains the significance of the technology, the reimbursement scheme and outlines the next steps for EBR as it prepares for commercial roll out.
This podcast was developed in collaboration with EBR Systems, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Originally published as Vital Signs Podcast: EBR's major milestones in WiSE CRT commercialisation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
2 hours ago
- News.com.au
Top 10 at 11: ASX ticks up as gold stocks extend gains; CDE brings ex-Nvidia AI expert onboard
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Gold prices lift again Spot gold climbed 1.1% overnight, hitting US$3433.5 per ounce as US bond yields continue to fall. That momentum has given the ASX a shot in the arm, up 0.35% in the first hour of trade with the materials sector up 1.95% and the All Ords Gold index climbing 2.31%. Healthcare is dragging in the other direction, down 0.64% while the ASX 200 Banks index slides lower yet again, down 0.41%. After a back-and-forth day of essentially flat trade yesterday, it'll be interesting to see whether the bulls or the bears come out on top today. WINNERS Code Name Last % Change Volume Market Cap CDE Codeifai Limited 0.026 44% 18576226 $8,494,218 GTE Great Western Exp. 0.015 36% 2155603 $6,245,337 FAU First Au Ltd 0.005 25% 3855928 $8,305,165 1CG One Click Group Ltd 0.011 22% 3614212 $10,640,575 ALY Alchemy Resource Ltd 0.006 20% 667502 $5,890,381 AUR Auris Minerals Ltd 0.006 20% 84033 $2,383,130 AON Apollo Minerals Ltd 0.007 17% 72800 $5,570,741 ATS Australis Oil & Gas 0.008 14% 6353533 $9,226,437 DTM Dart Mining NL 0.004 14% 2968000 $4,193,195 ICR Intelicare Holdings 0.016 14% 62500 $6,806,634 In the news... Codeifai (ASX:CDE) has brought ex-Nvidia AI and machine learning expert Rafael Possas onto its strategic advisory panel as the company completes acquisition of to be redubbed as the QuantumAI Secure platform. The secured payment platform is AI-driven and quantum-secured, safeguarding payments, file transfers and end-to-end communications. First AU (ASX:FAU) has initiated a 3000m drilling program at the Nimba gold project after an extensive surface mapping program over a 10 square kilometre area. FAU is looking for a potential ore body, delving into the local geological system in the search for fresh gold mineralisation. Life admin company One Click Group (ASX:1CG) has exceeded its 2024 July revenue numbers in just 18 days this year, pulling in $2.2m in revenue in just over two weeks. The company's returning customer lodgement rate also increased, rising to 72% compared to 63% the previous year. LAGGARDS Code Name Last % Change Volume Market Cap EEL Enrg Elements Ltd 0.001 -50% 385807 $6,507,557 RLG Roolife Group Ltd 0.003 -25% 19000 $6,371,125 CLA Celsius Resource Ltd 0.006 -14% 1390 $21,948,419 IPB IPB Petroleum Ltd 0.006 -14% 10000 $4,944,821 SPX Spenda Limited 0.006 -14% 515855 $32,306,508 TG1 Techgen Metals Ltd 0.021 -13% 225395 $3,807,977 ANO Advance Zinctek Ltd 0.97 -12% 2000 $68,910,718 HMI Hiremii 0.048 -11% 20000 $7,944,231 KGD Kula Gold Limited 0.008 -11% 1445684 $8,291,283 IND Industrialminerals 0.135 -10% 13465 $12,048,375
Herald Sun
2 hours ago
- Herald Sun
Big Tech braces as JPMorgan warns of crowding
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Big Tech faces earnings test this week JPMorgan warns crowding is off the charts Neuren shows what happens when everyone's already in This is one of those weeks where Aussie investors in US tech companies hold their breath and hit refresh every morning. The 'Magnificent Seven' earnings parade kicks off tonight in the US, with Alphabet and Tesla first on deck. Investors will be running the ruler over these results, as these are the numbers that could make or break a narrative. For months now, the market's been sprinting ahead, pricing in a future where AI saves the economy, cures disease, and maybe even folds your laundry. But now it's time for reality to catch up. Alphabet needs to prove it's more than just ads and AI PowerPoints. Tesla needs to prove it's still an automaker, not just a proxy for Elon's fanbase. Wall Street's expectations aren't exactly modest. Analysts reckon S&P 500 companies will post 5.6% earnings growth for Q2, the slowest pace in three quarters, but still enough to keep the bulls hopeful. The Mag Seven alone are tipped to deliver 14.1% growth, while the other 493 stocks limp along at just 3.4%. In other words, Big Tech pretty much drives the whole index now. That kind of concentration might excite momentum traders, but it's making the strategists nervous. And that's why JPMorgan hoisted the red flag earlier this week. When too many people squeeze into the same boat JPMorgan's top quant Dubravko Lakos-Bujas warned investors are piling into high-octane tech names at "100th percentile" crowding levels – the most extreme in 30 years. Palantir, Coinbase, Nvidia, all momentum darlings, are now packed to the gills with hot money. In just three months, positioning in these 'high-beta' stocks rocketed from the 25th percentile to the 100th, the fastest spike the bank's seen since it started tracking this stuff in the early '90s. Why does this matter? Because when everyone's already long, there aren't many fresh buyers left to keep the rally going, and if sentiment even twitches, the rush for the exit can get messy. That's what JPMorgan calls overcrowding, and right now, it's not a stock-specific issue. It's a market-wide signal that complacency may be setting in, right when the music could be slowing. 'We believe the current 100% percentile crowding based on our quantitative analysis not only presents a risk for this crowded segment, but is also a red flag for the broader market implying there is rising complacency in the short term,' wrote Lakos-Bujas. He added this has been driven by a combination of markets increasingly pricing in a goldilocks outcome, tariff exhaustion, and institutional investors chasing more speculative equity segments of the market. So what exactly is '100th percentile crowding'? When portfolio strategists say a stock is in the 100th percentile for crowding, they don't mean everyone owns it. They mean it's more owned and more positioned-for than 99% of other stocks in the same universe. Analysts look at things like fund ownership, retail trading spikes, short interest, even Google searches and Reddit threads. They mush it all into a 'crowding score,' then rank every stock from least to most crowded. If yours lands in the top 1%, you're in the 100th percentile. It's about positioning risk. And that risk doesn't show up in P/E ratios, it shows up when the herd changes direction. That's why hedge funds track it obsessively. If a stock is over-loved, even good news might not be enough to keep it afloat. Could Aussie stocks be crowded too? Let's bring it home. The ASX might not have a Magnificent Seven, but we've got our own examples of crowding: stocks that got so much love, so quickly, they became vulnerable to their own popularity. Neuren Pharmaceuticals (ASX:NEU) is probably a case in point. After its Rett Syndrome drug Daybue got FDA approval via its US partner Acadia, the stock took off. Retail punters jumped on board. Funds bulked up. Liquidity was thin, and soon, Neuren was sitting at the top of the small-cap biotech pile, likely in the 95th to 100th percentile of ownership concentration among its peers. The stock ran past $25, but then started drifting back to the $12–13 range, not because the story changed but because investors who wanted in were already there. That's crowding in action. Source: Google That's not to say Neuren is a bad company. Far from it. But when positioning is maxed out, the risk/reward flips ... and it doesn't take much for the herd to bolt. This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decision. Originally published as Big Tech braces for judgment week, as JPMorgan flags extreme crowding
News.com.au
7 hours ago
- News.com.au
Biocurious: The cannabis stocks that stand out in a field of weeds
Cannabis suppliers are struggling to differentiate themselves in a commoditised market Regulators have lax telehealth prescribers in their sights Althea Group has sold its medical pot arm in favour of THC-infused beverages Having sprouted in a field of hope and hype eleven years ago, the ASX medicinal cannabis sector has wilted in the face of unrealistic expectations and misguided strategies. Demand isn't the problem: patients have embraced medical weed zealously since it was legalised a decade ago. Globally, most western countries have sanctioned both medical usage and many have condoned recreational indulgence (including most US states). Because there's only two approved cannabis treatments, local dispensing is largely carried out via an authorised prescriber scheme. In the six months to December 2024, these docs wrote 377,840 prescriptions. Of these, 230,091 were for products with a THC content of more than 98%. Patients aren't mucking around. What's not to like? The answer is rampant oversupply of the green stuff coupled with the rise of telehealth clinics, some of which are being criticised for alleged 'tick and flick' dispensing practices. Echoing Australian Medical Association concerns, Little Green Pharma (ASX:LGP) CEO Paul Long refers to 'poor actors' in the local market. 'Reports constantly refer to a handful of doctors, often junior doctors that are either being coerced, or paid exorbitant money to write a huge volume of THC scripts,' he says. 'I agree it is an issue and calling it out for the long-term growth of our industry is important." He adds hundreds of thousands have tried medical cannabis when nothing has worked, with great success. Reflecting the 'commoditised' market, Althea Group (ASX:AGH) in May sold its local medical cannabis business, Tasmanian Botanics Pty Ltd for a knock-down $1 million. 'The market has become irrational,' says Althea CEO Joshua Fegan. 'It's very saturated, with product from places like Canada, South Africa and Colombia'. He says most of the consumption is by way of dried flower, which implies folk might be smoking the devil's lettuce for jollies rather than using it medicinally. We'll delve further into Althea's new direction below. The dope on how to get it right While most suppliers have withered, a handful prosper via differentiated strategies and perhaps a bit of luck. They are producing meaningful revenues and – in some cases - profits. The Perth-based Little Green Pharma derives 80% of its revenue from the local market, but its greater fortunes align to the rapidly evolving European market. Germany is in the throes of partial legalisation. In France, the company supplies a pilot program that's a precursor to legalisation. Little Green's owns a production facility in Denmark – Europe's biggest – purchased from Canada's Canopy Growth for a knock-down $20 million three years ago. Two hours from the German border, the facility provides a streamlined route to the biggest Continental markets. 'It's very unlikely a site like this will be built again in the foreseeable future,' Little Green CEO Paul Long says. Meanwhile, the company's Busselton facility becomes a 'craft' producer of a small amount of slowly cured, hand trimmed, genetically superior stuff. Naturally, this attracts a better margin. In the year to March 2025 Little Green grew its revenue by 43%, to a record $36.8 million 'against a backdrop of significant regulatory change and intense competition'. European revenues doubled. Adjusted for non-cash items, Little Green managed underlying earnings of $2.9 million compared with a previous $1.6 million loss. From gummies to suppositories Bioxyne (ASX:BXN) has a modest $64 million market cap, but that's big enough to confer 'sector leader' status. Bioxyne's engine room is Breathe Life Sciences (BLS), acquired via scrip in 2023. BLS makes and distributes medical cannabis and other consumer health products, either under its own brands or third-party labels. (locally, Bioxyne is also the only licensed maker of MDMA and psilocybin for authorised prescribers and pyschedelic clinical trials). In 2019 the company launched in the UK and Japan via its well-known Dr Watson brand, covering everything from gummies, to vapes to suppositories. BLS too has entered the German market with a deal to supply a minimum 1.6 tonnes of cannabis flower and finished product to two clients. The company expects the agreement will reap a minimum of $5.6 million of revenue in the 2025-26 year. Ja, das ist gut! Bioxyne CEO Sam Watson expects German demand to rapidly overtake the $1 billion a year Australian market. On June 12 the company upgraded full-revenue expectations from $25 million to $28 million, a lofty step up from the previous year's $9.65 million. The Ebay of medicinal dope Formerly known as Cronos Australia, Vitura Health (ASX:VIT) doesn't produce any of its own material, but operates a marketplace that sells hundreds of flowers and oils from third party suppliers. Vitura also has expanded into prescription nicotine vapes. The company has built a network of physical and online prescribers, mainly via acquisition. Vitura owns the Canview marketplace, Doctors on Demand telehealth business, CDA Clinics (medical cannabis telehealth) and the clinic chain Candor Medical. In May, Vitura's 50% joint venture Flora acquired the digital platform Heyday Medical, 'one of Australia's most respected medicinal cannabis clinics'. Established in 2020, the chain claims to have serviced more than more than 5000 patients. Last November Flora acquired the Releaf Group, which operates telehealth and physical clinics. In a March quarter update, Vitura said full-year revenue was unlikely to meet the targeted 10% improvement. But the June quarter implies a yearly run rate of $138 million, up 11%. Management also expects a 20% improvement on last year's normalised underlying earnings of $8.4 million. Putting the pep into soft drinks Coming back to Althea, the company's new schtick is entering the North American market for THC-infused beverages. (THC is the psychoactive component of cannabis). Yep, these bevvies are legal in Canada and the US and are sold in bottle shops alongside alcohol. Althea's foray is by way of its subsidiary Peak. Althea's Fegan says when Peak started producing in 2021, only 4% of cannabis consumers had tried these drinks. Now, the number is more like one-quarter of them. He says the drinks have a similar effect to a similar sized serve of alcohol, but without the hangover. 'It ticks a lot of boxes as a good consumer product,' he says. Peak's competitive edge is its technique to produce the THC emulsion, without the 'planty' taste of dope. Peak's offerings include seltzers, sodas and mocktails – but it's not yet putting the 'pep' into Pepsi. Peak Canada has just launched its own brand Snap Back, a heady mix of THC and rosin (pine resin). By December Althea expects to have four or five US production sites, as close to distributors as possible. 'These big alcohol companies are looking closely at this space and our job is to develop drinks for those type of companies and produce them at scale," Fegan says. In the December half, Althea derived $8.2 million of revenue in Canada and the company expects this to grow during the summer months. Given the sale of its Australian business, Althea in May withdrew its full-year guidance of revenue between $26-33 million and underlying earnings of $800,000 to $1.1 million. Althea lost $2.6 million in the March quarter. But Fegan says the company should be cash flow positive without the drag of the divested Australian business.
